Premium
Effect of recombinant human interleukin‐11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin‐6
Author(s) -
Yonemura Yuji,
Kawakita Makoto,
Masuda Tetsuya,
Fujimoto Kouji,
Takatsuki Kiyoshi
Publication year - 1993
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1993.tb03020.x
Subject(s) - thrombopoiesis , interleukin 11 , in vivo , recombinant dna , interleukin 1β , interleukin , immunology , interleukin 3 , interleukin 2 , medicine , cancer research , cytokine , biology , microbiology and biotechnology , biochemistry , megakaryocyte , stem cell , haematopoiesis , immune system , genetics , t cell , gene , il 2 receptor
Summary. The ability of recombinant human interleukin‐11 (IL‐11) to stimulate rat megakaryopoiesis and thrombopoiesis in vivo was investigated. Once daily subcutaneous injections of IL‐11 at doses of 2, 8 and 20 μg/rat for 5 d caused dose‐dependent increases in platelet counts. The chronic administration of 20 μg/rat/d for 14 d resulted in biphasic increases in platelet counts with peaks at days 8 and 15 of up to 30% over the control, continuing for more than 5 d after cessation of IL‐11 injections. Moreover, a striking increase in megakaryocytic size and ploidy in bone marrow in response to IL‐11 was elicited. IL‐11 induced a dose‐dependent elevation in bone marrow cell numbers but not in splenic weight and cell numbers. Modifications of these parameters were noted as soon as 24 h after the first IL‐11 injections. IL‐11 had a same potency of thrombopoietic effect in rats as compared with IL‐6. However, elevation of acute phase protein such as immunosuppressive acidic protein was 2–2‐fold in rats given 20 μg/d of IL‐6 over those receiving a same dose of IL‐11 (470 v 210 μg/ml). In addition, the rate of body‐weight increase in rats receiving IL‐11 for 5 d as well as 14 d did not differ from that in control animals. In IL‐6 treated rats, the increase in body weight was significantly slower than the controls, which was observed even in the group given 8 μg/d of IL‐6. These results suggest that IL‐11 may be an effective strategy for the treatment of thrombocytopenia.